Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15098648 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA7CHRNA4SCN10ACDC7 | |
| Hydrochloric Acid SCHEMBL240506 | 0.98 | CHRNB2 (0.40) | CHRNB2CHRNA7CHRNA4SCN10ACDC7 | |
| Hydrochloric Acid SCHEMBL240507 | 0.98 | CHRNB2 (0.40) | CHRNB2CHRNA7CHRNA4SCN10ACDC7 | |
| SCHEMBL23247498 | 0.95 | MEN1 (0.42) | CHRNB2CHRNA7CHRNA4SCN10ACDC7 | |
| SCHEMBL1812334 | 0.79 | CHRNB2 (0.41) | CHRNB2CHRNA7CHRNA4SCN10AMEN1 | |
| SCHEMBL47075 | 0.79 | CHRM2 (0.41) | CHRNB2CHRNA7CHRNA4SCN10ACDC7 | |
| SCHEMBL18058878 | 0.79 | CHRNB2 (0.41) | CHRNB2CHRNA7CHRNA4SCN10ACDC7 | |
| SCHEMBL8751908 | 0.79 | CHRNB2 (0.41) | CHRNB2CHRNA7CHRNA4SCN10AMEN1 | |
| SCHEMBL13505409 | 0.79 | CHRNB2 (0.41) | CHRNB2CHRNA7CHRNA4SCN10AMEN1 | |
| SCHEMBL12672828 | 0.79 | CHRM2 (0.41) | CHRNB2CHRNA7CHRNA4SCN10ACDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445367-B1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-2945952-B1 | HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9809600-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-11-07 | — | — | US | disclosed |
| EP-3239153-A1 | 9-(1H-IMIDAZOL-5-YL)-1,11-DIHYDROISOCHROMENO[4',3':6,7]NAPHTHO[1,2-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HCV NS5A | Gilead Pharmasset LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2017184476-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017181383-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | WO | disclosed |
| EP-2907816-A1 | Condensed imidazolylimidazoles as antiviral compounds | Gilead Pharmasset LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014110705-A9 | HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-03-05 | — | — | WO | disclosed |
| EP-2435424-B1 | ANTIVIRAL COMPOUNDS COMPOSED OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | MERCK SHARP & DOHME (US) | 2015-01-21 | — | — | EP | disclosed |
| WO-2014110687-A1 | THIAZOLYL-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014110705-A1 | HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014110706-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014110688-A1 | THIOPHENE- SUB STITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2013075029-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012041014-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2010111483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CHRNB2 4874/4885CHRNA7 4847/4885CHRNA4 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.